Stock Events

Stock Events

Genmab 

$33.60
238
-$0.81-2.35% Friday 20:00
+$0.00+0%Friday 23:30After hours

Statistics

Day High
34.19
Day Low
33.55
52W High
35.43
52W Low
23.62
Volume
1,002,601
Avg. Volume
2,166,579
Mkt Cap
20.65B
P/E Ratio
22.14
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
3.13
16.01
28.89
41.76
Expected EPS
23.7273750264
Actual EPS
N/A

Financials

25.89%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.72BRevenue
963MNet Income

Analyst Ratings

39.25Average Price Target
The highest estimate is 43.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GMAB. It's not an investment recommendation.
Microsoft
54
MSFT
Novo Nordisk
53
NOVO-B.CO
NVIDIA
40
NVDA
Amazon
37
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in biotechnology, directly competing with Genmab in the development of monoclonal antibodies and cancer treatments.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. competes in the biotech space, focusing on innovative therapeutics, including those for cancer, which overlaps with Genmab's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its work in monoclonal antibodies, directly competing with Genmab in several therapeutic areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. operates in the biopharmaceutical field, competing with Genmab in the development of treatments for diseases such as cancer.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company competes with Genmab in the oncology sector, particularly in the development of innovative cancer treatments.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that competes with Genmab in the development of cancer therapies and immunotherapy treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis AG competes with Genmab in the pharmaceutical and biotechnology sectors, particularly in the development of innovative medicines, including cancer treatments.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a global pharmaceutical company that competes with Genmab in the development of drugs for various diseases, including cancer.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC is involved in the discovery and development of pharmaceuticals for several diseases, including cancer, making it a competitor to Genmab.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson operates in the pharmaceutical and biotechnology sectors, competing with Genmab in the development of innovative treatments for diseases, including cancer.

About

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Show more...
CEO
Jan van de Winkel
Employees
3119
Country
Denmark
ISIN
US3723032062
WKN
000A1WZYB

Listings

MX
MX
GMAB1N.MX
MX
MX
GMABN.MX
STU
DE
GE91.STU
XETRA
DE
GE9.XETRA

0 Comments

Share your thoughts

FAQ

What is Genmab stock price today?▼
The current price of GMAB is $33.60 USD — it has decreased by -2.35% in the past 24 hours. Watch Genmab stock price performance more closely on the chart.
What is Genmab stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Genmab stocks are traded under the ticker GMAB.
Is Genmab stock price growing?▼
GMAB stock has risen by +1.11% compared to the previous week, the month change is a +14.83% rise, over the last year Genmab has showed a +22% increase.
What is Genmab market cap?▼
Today Genmab has the market capitalization of 20.65B
When is the next Genmab earnings date?▼
Genmab is going to release the next earnings report on November 05, 2026.
What were Genmab earnings last quarter?▼
GMAB earnings for the last quarter are 4.91 USD per share, whereas the estimation was 3.56 USD resulting in a +37.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Genmab revenue for the last year?▼
Genmab revenue for the last year amounts to 3.72B USD.
What is Genmab net income for the last year?▼
GMAB net income for the last year is 963M USD.
How many employees does Genmab have?▼
As of September 05, 2026, the company has 3,119 employees.
In which sector is Genmab located?▼
Genmab operates in the Health & Wellness sector.
When did Genmab complete a stock split?▼
The last stock split for Genmab was on May 01, 2018 with a ratio of 5:1.
Where is Genmab headquartered?▼
Genmab is headquartered in Copenhagen, Denmark.